Merck's chief science and technology officer Laura Matz said that Innerva's platform could become "a true enabler for digital personalised treatment of patients suffering from severe and chronic ...

“Digitalisation is key to our long-term growth strategy,” commented Laura Matz, chief science and technology officer of Merck, who noted the DevTools provide consistent digital ‘blueprints ...

Merck KGaA lowered its medium-term outlook for its healthcare and life-science segment due to China challenges and recent ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

It is hard to get excited after looking at Merck's (NYSE:MRK) recent performance, when its stock has declined 13% over the past three months. However, stock prices are usually driven by a company ...

Merck has struck a $1.3 billion deal to buy Eyebiotech ... Hopkins at [email protected] and Laura Cooper at [email protected] ...

Sept 25 (Reuters) - Merck (MRK.N), opens new tab said on Wednesday a combination of its experimental drug and blockbuster therapy Keytruda failed a late-stage trial testing it in previously ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Merck (MRK) closed the latest trading day at $113.09, indicating a -1.43% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.4%. Elsewhere, the Dow gained 0. ...

Laura Ingraham is the host of FOX News Channel's (FNC) The Ingraham Angle (weeknights, 7 PM/ET). She joined the network in 2007 as a contributor. Read More As the host of The Ingraham Angle ...